OCX - OncoCyte Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
1.6600
+0.0500 (+3.11%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.6100
Open1.6500
Bid1.6600 x 800
Ask1.6900 x 1300
Day's Range1.6400 - 1.7200
52 Week Range1.1650 - 6.9200
Volume304,448
Avg. Volume177,651
Market Cap86.275M
Beta (3Y Monthly)4.83
PE Ratio (TTM)N/A
EPS (TTM)-0.3970
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.03
  • GlobeNewswire

    OncoCyte Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    DetermaVu CLIA Validation Remains On-Track for Q1 2020 Completion Acquisition of Razor Genomics Lung Cancer Treatment Stratification Test with Proposed CMS Positive.

  • GlobeNewswire

    OncoCyte to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    ALAMEDA, Calif., Nov. 11, 2019 -- OncoCyte Corporation (NYSE American: OCX) today announced that it will release its financial and operating results for the third quarter ended.

  • GlobeNewswire

    Oncocyte Announces Strategic Support of GO2 Foundation for Lung Cancer

    GO2 Foundation was founded by patients and survivors of lung cancer and is the world’s leading organization dedicated to saving, extending and improving the lives of those vulnerable, at risk and diagnosed with lung cancer.

  • GlobeNewswire

    OncoCyte to Present Data on Physician Decision Making around Lung Nodule Management for the Early Diagnosis of Lung Cancer at the Managed Care Conference AMCP Nexus 2019

    OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data at AMCP Nexus 2019, being held October 29-November 1, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, MD. The poster details findings from a physician survey showing limited use of current guidelines and risk models for lung nodule management in the community setting, resulting in overuse of risky and expensive diagnostic procedures, even for small, low risk nodules. OncoCyte is a molecular diagnostics company providing actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment.

  • GlobeNewswire

    OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019

    OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. OncoCyte is a molecular diagnostics company providing actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The company is currently developing a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence, allowing them to be treated when their cancer is still responsive to adjuvant chemotherapy.

  • What Kind Of Shareholders Own OncoCyte Corporation (NYSEMKT:OCX)?
    Simply Wall St.

    What Kind Of Shareholders Own OncoCyte Corporation (NYSEMKT:OCX)?

    The big shareholder groups in OncoCyte Corporation (NYSEMKT:OCX) have power over the company. Insiders often own a...

  • GlobeNewswire

    OncoCyte Closes Initial Investment in Razor Genomics and Acquires Rights to Commercialize Razor Lung Cancer Treatment Stratification Test

    OncoCyte Corporation (“OncoCyte”) (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced that it has closed its previously announced initial investment in a 25% preferred stock interest in Razor Genomics, Inc. (“Razor”) and has acquired rights to commercialize Razor’s CLIA-validated lung cancer treatment stratification test. The Razor test enables the identification of early-stage lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.

  • Thomson Reuters StreetEvents

    Edited Transcript of OCX earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q2 2019 OncoCyte Corp Earnings Call

  • GlobeNewswire

    OncoCyte Announces Definitive Agreement to Acquire Razor Genomics

    OncoCyte Corporation (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced that it has entered into a definitive agreement to acquire Razor Genomics.  An initial closing at which OncoCyte will acquire shares of Razor preferred stock representing 25% of the outstanding equity of Razor, is expected to close by the end of September, subject to customary and other closing conditions. OncoCyte will have the option to acquire the balance of the outstanding shares of Razor common stock from Razor’s shareholders (the “Purchase Option”).

  • GlobeNewswire

    OncoCyte Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    Molecular Diagnostics industry veteran Ron A. Andrews appointed CEO Melinda Griffith elected to Board of Directors Strengthened Clinical Operations and Commercial Marketing.

  • GlobeNewswire

    OncoCyte to Report Second Quarter 2019 Financial Results on Wednesday, August 14, 2019

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter ended June 30, 2019, on Wednesday, August 14, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, August 14, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. To access the live webcast, go to the investor relations section on the Company’s website, http://public.viavid.com/index.php?id=135362.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation

    NEW YORK , July 26, 2019 /PRNewswire/ -- Acer Therapeutics Inc. (ACER) Lifshitz & Miller announces investigation into possible securities laws violations in connection with a CRL for EDSIVO. If you are ...

  • GlobeNewswire

    OncoCyte Strengthens Board of Directors with Addition of Industry Veteran Melinda Griffith

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, molecular diagnostic tests for the early detection and management of cancer, today announced the appointment of Melinda Griffith to its Board of Directors. “We are delighted to have Melinda, an accomplished life sciences industry executive, join our board during this exciting time of growth for OncoCyte,” said Ronald Andrews, President and Chief Executive Officer. Ms. Griffith is a senior executive with extensive experience leading the business development, licensing and legal activities of diagnostic, device and pharmaceutical companies.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OncoCyte Corporation - OCX

    NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Pomerantz LLP is investigating claims on behalf of investors of OncoCyte Corporation (“OncoCyte” or the “Company”) (NYSEAMERICAN: OCX). Such investors are advised ...

  • Is OncoCyte Corporation (NYSEMKT:OCX) Trading At A 47% Discount?
    Simply Wall St.

    Is OncoCyte Corporation (NYSEMKT:OCX) Trading At A 47% Discount?

    Does the July share price for OncoCyte Corporation (NYSEMKT:OCX) reflect what it's really worth? Today, we will...

  • GuruFocus.com

    Insiders Roundup: OncoCyte, BioSciences

    Largest insider trades of the week

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of OncoCyte Corporation (OCX)

    NEW YORK, NY / ACCESSWIRE / July 2, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OncoCyte Corporation ("OncoCyte" or the "Company") ...

  • GlobeNewswire

    OncoCyte Provides Mid-Year Update

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional time to complete its ongoing CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer. In the CLIA Validation Study, started in late April, OncoCyte is assaying approximately 120 samples previously tested in its R&D Validation study, with the goal of demonstrating that the same results can be obtained in the Company’s CLIA-validated laboratory.

  • Benzinga

    The Companies Set To Join The Russell Index July 1

    OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...

  • GlobeNewswire

    OncoCyte to be Added to the Russell 2000®, 3000® and Microcap Indexes

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective when the U.S. markets open on July 1, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index. “We are pleased to be joining these three Russell indexes,” commented William Annett, President and CEO of OncoCyte.

  • GlobeNewswire

    OncoCyte Announces Chief Executive Officer Transition

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that diagnostics industry veteran and current Board member Ronald Andrews will assume the role of Chief Executive Officer, effective July 1. Mr. Andrews brings to OncoCyte over 30 years of diverse experience in the clinical and molecular diagnostics field, with a particular focus on oncology.

  • GlobeNewswire

    OncoCyte Announces Participation at the 2019 BIO International Convention

    ALAMEDA, Calif., May 29, 2019 -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that.